Skip to main content
Clinical Trials/IRCT201206279801N3
IRCT201206279801N3
Completed
Phase 3

Comparison of efficacy and adverse effects of filgrastim produced by Samen pharmaceutical company and neupogen as a standard drug in Breast Cancer Patients

Samen Pharmaceutical Company0 sites168 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Breast cancer.
Sponsor
Samen Pharmaceutical Company
Enrollment
168
Status
Completed
Last Updated
8 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
8 years ago
Study Type
Interventional
Sex
Female

Investigators

Sponsor
Samen Pharmaceutical Company

Eligibility Criteria

Inclusion Criteria

  • Age\>18 yr; Diagnosis of locally advanced breast cancer; WHO Performance Status less than or equal of 2; Absence of neutropenia (ANC \<1500/mm3\) before starting chemotherapy; Completing the Consent form.
  • Exclusion criteria: History of hypersensitivity reaction to biologic drugs; Existence of renal failure ; Existence of hepatic failure ; Coadministration of neutropoietic drugs; Existence of cardiac arrythmia.

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Not specified

Similar Trials